ArticlePLoS computational biology2025
Replicability of bulk RNA-Seq differential expression and enrichment analysis results for small cohort sizes.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A Conserved Macrophage-to-Hepatic Stellate Cell PDGF Axis in Human MASH Identified by Multi-Cohort sc/snRNA-Seq Re-Analysis.International journal of molecular sciences · 2026Article
- A module-based approach for post-omics, post-GWAS network-based gene classification.Bioinformatics (Oxford, England) · 2026Article
- Y Chromosome Haplogroups and Susceptibility to Esophageal Squamous Cell Carcinoma: An Exploratory Association and Diagnostic Modeling Study.Molecular genetics & genomic medicine · 2026Article
- Transcriptomic Profiling Identifies Disease-Specific miRNA-mRNA Regulatory Networks in Systemic Sclerosis.Biomolecules · 2026Article
- Cytokine-induced PD-L1 and PD-L2 expression is preserved but reverse signalling is altered in rheumatoid arthritis fibroblast-like synoviocytes.Arthritis research & therapy · 2026Article
- Network-based exploration of 4-(phenylsulfonyl)morpholine molecules for metastatic triple-negative breast cancer suppression.PLoS computational biology · 2026Article
- Alterations in energy production in aFrontiers in aging neuroscience · 2026Article
- MicroRNA Enrichment and Docking-Based Evaluation of Ilomastat Targeting of MMP-2 in Esophageal Squamous Cell Carcinoma: Insights from a South African Cohort.Computational and structural biotechnology journal · 2026Article
- Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types.Frontiers in oncology · 2026Article
- Differential activity of transcription factors and neuronal effectors during the development of pikeperch brain.Biology open · 2025Article
- Next-Generation Sequencing: A Review of Its Transformative Impact on Cancer Diagnosis, Treatment, and Resistance Management.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The high-dimensional and heterogeneous nature of transcriptomics data from RNA sequencing (RNA-Seq) experiments poses a challenge to routine downstream analysis steps, such as differential expression analysis and enrichment analysis. Additionally, due to practical and financial constraints, RNA-Seq experiments are often limited to a small number of biological replicates. In light of recent studies on the low replicability of preclinical cancer research, it is essential to understand how the combination of population heterogeneity and underpowered cohort sizes affects the replicability of RNA-Seq research. Using 18'000 subsampled RNA-Seq experiments based on real gene expression data from 18 different data sets, we find that differential expression and enrichment analysis results from underpowered experiments are unlikely to replicate well. However, low replicability does not necessarily imply low precision of results, as data sets exhibit a wide range of possible outcomes. In fact, 10 out of 18 data sets achieve high median precision despite low recall and replicability for cohorts with more than five replicates. To assist researchers constrained by small cohort sizes in estimating the expected performance regime of their data sets, we provide a simple bootstrapping procedure that correlates strongly with the observed replicability and precision metrics. We conclude with practical recommendations to alleviate problems with underpowered RNA-Seq studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.